Neutralizing antibodies and efficacy of interferon β-1a: A 4-year controlled study

Neurology

Volumn 65, Issue 1, 2005, Pages 40-47

  Kappos, L ^a   Clanet, M ^b   Sandberg Wollheim, M ^e   Radue, E W ^a   Hartung, H P ^c   Hohlfeld, R ^d   Xu, J ^f   Bennett, D ^f   Sandrock, A ^f   Goelz, S ^f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CHU PURPAN   (France)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Neurology Clinic   (Germany)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SERODIAGNOSIS; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; CENTRAL NERVOUS SYSTEM; DISABILITY EVALUATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 22044450811     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000171747.59767.5c     Document Type: Article

References (30)

1. Prout TE. The antigenicity of insulin: a review. J Chronic Dis 1962;15:879-885.
2. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 1980;51:691-697.
3. Lusher JM. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica 2000;85(suppl to 10):2-6.
4. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 1998;18:345-350.
5. Myhr KM, Ross C, Nyland HI, Bendtzen K, Vedeler CA. Neutralizing antibodies to interferon (IFN) α-2a and IFNβ-1a or IFNβ-1b in MS are not cross-reactive. Neurology 2000;55:1569-1571.
6. Colamonici OR, Pfeffer LM, D'Alessandro, F, et al. Multichain structure of the IFN-α receptor on hematopoietic cells. J Immunol 1992;148:2126-2132.
7. Hu R, Gan Y, Liu J, Miller D, Zoon KC. Evidence for multiple binding sites for several components of human lymphoblastoid interferon-α. J Biol Chem 1993;268:12591-12595.
8. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
9. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
10. Darnell JE Jr, Kerr, IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
11. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Unavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
12. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
13. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
14. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
15. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
16. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology 2003;60:37-43.
17. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001;56:1496-1504.
18. European Study Group on Interferon-Beta-1a in MS. Double-blind randomized multicenter dose-comparison study of interferon-β-1a: rationale, design and baseline data. Mult Scler 2001;7:179-183.
19. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002;59:1507-1517.
20. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986;119:558-573.
21. Goodkin DE, Priore RL, Wende KE, et al. Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. Multiple Sclerosis 1998;4:480-486.
22. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco, Mutani R. Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000;48:95-100.
23. Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-1408.
24. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
25. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037.
26. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
27. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
28. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
29. Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004;3:305-309.
30. Kappos L, Polman C, Pozzilli MD, et al. Final analysis of the European multicenter trial on IFN β-1b in secondary progressive MS. Neurology 2001;57:1969-1975.